DefiniGEN's Head of R&D, Nikolaos Nikolaou, will be presenting "Optimised iPSC-derived hepatocytes (Opti-HEP) as a novel in vitro platform in drug efficacy and toxicity screening" at this exciting symposium organised by the Consortium for Regenerative Hepatology.